HTG Molecular Diagnostics to Announce Second Quarter 2020 Financial Results and Host Conference Call on Tuesday, August 11
HTG Molecular Diagnostics (HTGM) will announce its Q2 financial results on August 11, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HTG Molecular Diagnostics (HTGM) will announce its Q2 financial results on August 11, 2020, after market close. Management will discuss these results and provide an update in a conference call at 4:30 PM ET. The company specializes in next-generation sequencing (NGS) molecular profiling, utilizing its HTG EdgeSeq technology to analyze solid and liquid samples for precision medicine. This technology aids in identifying important biomarkers and understanding their clinical relevance.
Details
News Market Reaction – HTGM
The recorded move for HTGM in the trading session of this news was -4.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., Aug. 05, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2020 after the market close on Tuesday, August 11, 2020. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
| Conference Call & Webcast Details | |
| Date: | Tuesday, August 11 |
| Time: | 4:30 pm Eastern Time |
| Toll Free: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13706480 |
| Webcast: | http://public.viavid.com/index.php?id=140583 |
About HTG
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.